<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="interaction" /><meta name="keywords" content="" /><title>Analgesics: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../383/theme.css" /><link type="text/css" rel="stylesheet" href="204/style.css" /><link type="image/x-icon" rel="shortcut icon" href="../../favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="bnf_int56-analgesics.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.8/jquery.min.js"></script><script type="text/javascript" src="../../383/scripts.js"></script><style type="text/css">
          .contentsbox { position: fixed; z-index:1001; }
          .contentsbox_wrap { overflow: hidden; width: 20px; height: 130px; position: absolute; left: 0; top: 0; }
        </style><!--[if IE 8]>
          <style type="text/css">
          #p1 {
          float: left;
          padding-bottom: 15em;
          }
          </style>
          <![endif]--><!--[if lte IE 8]>
          <style type="text/css">
          #start-search input {
          height: 28px;
          padding-top: 8px;
          }
          @media screen {
          #pV {
          display: block !important;
          }
          }
          </style>
          <![endif]--><!--[if IE 7]>
          <style type="text/css">
          #start-search input {
          position: absolute !important;
          left: 0;
          top: 0;
          }
          .as-shadow {
          margin-left: -4px !important;
          color: silver;
          }
          </style>
          <![endif]--><!--[if lte IE 7]>
          <style type="text/css">
          .menu {
          height: 1%;
          }
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }

          #account-info ul li a {
          width: 12em;
          }
          #opts ul li span {
          width: 12em;
          }
          div.as-select ul li ul li span {
          width: 40em;
          }
          div.menu ul li ul li {
          float: left !important;
          }
          #pQ fieldset, #qd, #input-box, #pub-list, #start-search, #end-search {
          display: inline;
          float: left;
          height: 100%;
          padding: 0;
          margin: 0;
          position: relative;
          }
          #hM a, #hM a img {
          border: none;
          display: inline-block;
          float: left;
          }
          #qd input {
          float: left;
          display: inline-block !important;
          }
          #start-search input {
          height: 28px;
          padding-top: 8px !important;
          }
          #end-search, #end-search input {
          height: 36px !important;
          }
          #hM, #content, #searchForm, #purple-menu {
          width: expression(document.body.clientWidth > 63 * parseInt(document.body.currentStyle.fontSize) ? '63em': 'auto');
          margin: 0 auto;
          }
          #pQ {
          z-index: 1;
          }
          </style>
          <![endif]--><!--[if lte IE 6]>
          <style type="text/css">
          body {
          height: 100%;
          }
          div.menu ul li a, div.menu ul li span {
          display: inline-block;
          }
          div.menu ul li ul li {
          clear: both;
          }
          div.as-select ul li span {
          height: 20px;
          padding-top: 16px;
          padding-left: 1em;
          padding-bottom: 0;
          padding-left: 1em;
          margin: 4px 0;
          border-right: 1px solid #888;
          background-image: url("images/dropdown_img.png");
          background-repeat: repeat-x;
          overflow-x: hidden;
          }
          div.as-select ul li ul li span {
          font: bold 10px Verdana !important;
          padding: 4px 1em !important;
          color: #2D2D2D;
          background: white;
          text-decoration: none !important;
          white-space: nowrap;
          border: none !important;
          float: left;
          }
          div.menu span.hover {
          background: #8F1F8D;
          color: white;
          }
          </style>
          <![endif]--></head><body><!--[if lte IE 6]>
          <script type="text/javascript">
          jQuery(document).ready(function($) {
          $('a.mclogo').html('<img src="images/mc_logo.gif" class="logo" />');
          });
          </script>
          <![endif]--><?highlighter off?><div id="hC"><div id="vH"><div id="pU"><a class="mclogo" href="http://www.medicinescomplete.com/about/"><img class="logo" src="../../images/mc_logo.png" alt="MedicinesComplete" /></a><div id="hM"><div id="vM" class="menu"><ul><li><a href="http://www.medicinescomplete.com/mc/index.htm">Home</a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm">Help</a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=bnf_int56-analgesics.htm">Feedback</a></li><li id="account-info"><a href="http://www.medicinescomplete.com/mc/account.htm">BNF.org Free Access</a><ul><li><a href="http://www.medicinescomplete.com/mc/account.htm">My Account</a></li><li><a href="http://www.medicinescomplete.com/mc/subscribe.htm">Subscribe</a></li><li><a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li><a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul></li></ul></div><a id="pD" accesskey="s" rel="bookmark" href="bnf_int56-analgesics.htm#pB" title="Skip Navigation">Skip Navigation</a></div></div><div id="pA"><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 13 Mar 2013 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="search-in">Publication</label><label for="q">Search for</label><div id="qd"><div id="start-search"><div class="as-select menu" id="pub-list"><ul><li><span>British National Formulary</span><ul></ul></li></ul></div><div id="input-box"><input type="text" id="q" name="q" accesskey="4" /></div></div><div id="end-search"><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div></div></div><div id="pH"><div id="pN"><div id="pT"><!--[if lte IE 7]>
             
            <![endif]--><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF March 2013</a> &gt; <a href="PHP8848-interactions.htm">Appendix 1 Interactions</a> &gt; <a href="PHP8852-list-of-drug-interactions.htm">List of drug interactions</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="bnf_int989-anakinra.htm" title="Previous: Anakinra">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="bnf_int58-nefopam.htm" title="Next: Nefopam">Next page</a> ►</div></div></div></div><div id="content"><div id="p1"><div id="pB"><?highlighter on?><h1>Analgesics</h1><?highlighter off?><?highlighter on?><div id="pC" class="jN"><p><strong>Analgesics</strong> has no specific interaction information.</p><p><strong>Nefopam</strong> belongs to <strong>Analgesics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int241-antidepressants-tricyclic.htm">Antidepressants, Tricyclic</a></td><td><p><span>side-effects possibly increased when </span><span>nefopam</span> <span>given with</span> <span>tricyclics</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int342-antimuscarinics.htm">Antimuscarinics</a></td><td><p><span>increased risk of antimuscarinic side-effects when </span><span>nefopam</span> <span>given with</span> <span>antimuscarinics</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Many drugs have antimuscarinic effects; concomitant use of two or more such drugs can increase side-effects such as dry mouth, urine retention, and constipation; concomitant use can also lead to confusion in the elderly. Interactions do not generally apply to antimuscarinics used by inhalation</p></div></td></tr><tr><td><a href="bnf_int257-maois.htm">MAOIs</a></td><td class="cAI"><p><span>manufacturer of </span><span>nefopam</span> <span>advises avoid concomitant use with</span> <span>MAOIs</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</p></div></td></tr></tbody></table><p><strong>Aspirin</strong> belongs to <strong>Analgesics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int551-acetazolamide.htm">Acetazolamide</a></td><td class="cAI"><p><span>increased risk of toxicity when high-dose </span><span>aspirin</span> <span>given with</span> <span>acetazolamide</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int110-antacids.htm">Antacids</a></td><td><p><span>excretion of </span><span>aspirin</span> <span>increased by alkaline urine due to some</span> <span>antacids</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</p></div></td></tr><tr><td><a href="bnf_int232-antidepressants-ssri.htm">Antidepressants, SSRI</a></td><td class="cAI"><p><span>increased risk of bleeding when </span><span>aspirin</span> <span>given with</span> <span>SSRIs</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int865-clopidogrel.htm">Clopidogrel</a></td><td><p><span>increased risk of bleeding when </span><span>aspirin</span> <span>given with</span> <span>clopidogrel</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int484-corticosteroids.htm">Corticosteroids</a></td><td><p><span>increased risk of gastro-intestinal bleeding and ulceration when </span><span>aspirin</span> <span>given with</span> <span>corticosteroids</span><span>, also <span>corticosteroids</span> reduce plasma concentration of salicylate</span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to corticosteroids used for topical action (including inhalation) unless specified</p></div></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span>increased risk of bleeding when </span><span>aspirin</span> <span>given with</span> <span>coumarins</span> <span>(due to antiplatelet effect)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int539-diuretics-loop.htm">Diuretics, Loop</a></td><td><p><span>possible increased risk of toxicity when high-dose </span><span>aspirin</span> <span>given with</span> <span>loop diuretics</span> <span>(also possible reduced effect of <span>loop diuretics</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int224-heparins.htm">Heparins</a></td><td class="cAI"><p><span></span> <span>aspirin</span> <span>enhances anticoagulant effect of</span> <span>heparins</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int783-ibuprofen.htm">Ibuprofen</a></td><td><p><span>antiplatelet effect of </span><span>aspirin</span> <span>possibly reduced by</span> <span>ibuprofen</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1015-iloprost.htm">Iloprost</a></td><td><p><span>increased risk of bleeding when </span><span>aspirin</span> <span>given with</span> <span>iloprost</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int14-kaolin.htm">Kaolin</a></td><td><p><span>absorption of </span><span>aspirin</span> <span>possibly reduced by</span> <span>kaolin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int511-methotrexate.htm">Methotrexate</a></td><td class="cAI"><p><span></span> <span>aspirin</span> <span>reduces excretion of</span> <span>methotrexate</span> <span>(increased risk of toxicity)—but for concomitant use in rheumatic disease see <a title="target-block: methotrexate cautions 10.1.3" href="PHP6599-methotrexate.htm#PHP6600">Methotrexate, section 10.1.3</a></span></p></td><td></td></tr><tr><td><a href="bnf_int613-metoclopramide.htm">Metoclopramide</a></td><td><p><span>rate of absorption of </span><span>aspirin</span> <span>increased by</span> <span>metoclopramide</span> <span>(enhanced effect)</span></p></td><td></td></tr><tr><td><a href="bnf_int60-nsaids.htm">NSAIDs</a></td><td class="cAI"><p><span>avoid concomitant use of </span><span>aspirin</span> <span>with</span> <span>NSAIDs</span> <span>(increased side-effects)</span></p></td><td><div class="cG"><p><strong>Note:</strong> <em>See also </em>Aspirin. Interactions do not generally apply to topical NSAIDs
</p></div></td></tr><tr><td><a href="bnf_int223-phenindione.htm">Phenindione</a></td><td class="cAI"><p><span>increased risk of bleeding when </span><span>aspirin</span> <span>given with</span> <span>phenindione</span> <span>(due to antiplatelet effect)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control  </p></div></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span></span> <span>aspirin</span> <span>enhances effects of</span> <span>phenytoin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int663-probenecid.htm">Probenecid</a></td><td><p><span></span> <span>aspirin</span> <span>antagonises effects of</span> <span>probenecid</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int549-spironolactone.htm">Spironolactone</a></td><td><p><span></span> <span>aspirin</span> <span>antagonises diuretic effect of</span> <span>spironolactone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int689-sulfinpyrazone.htm">Sulfinpyrazone</a></td><td><p><span></span> <span>aspirin</span> <span>antagonises effects of</span> <span>sulfinpyrazone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int42-thiopental.htm">Thiopental</a></td><td><p><span></span> <span>aspirin</span> <span>possibly enhances effects of</span> <span>thiopental</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int286-valproate.htm">Valproate</a></td><td><p><span></span> <span>aspirin</span> <span>enhances effects of</span> <span>valproate</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1223-varicella-zoster-vaccine.htm">Varicella-zoster Vaccine</a></td><td><p><span>possible risk of Reyes syndrome when </span><span>aspirin</span> <span>given with</span> <span>varicella-zoster vaccine</span><span>—manufacturers advise avoid <span>aspirin</span> for 6 weeks after giving <span>varicella-zoster vaccine</span></span></p></td><td></td></tr><tr><td><a href="bnf_int240-venlafaxine.htm">Venlafaxine</a></td><td class="cAI"><p><span>increased risk of bleeding when </span><span>aspirin</span> <span>given with</span> <span>venlafaxine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int859-zafirlukast.htm">Zafirlukast</a></td><td><p><span></span> <span>aspirin</span> <span>increases plasma concentration of</span> <span>zafirlukast</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Paracetamol</strong> belongs to <strong>Analgesics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int993-busulfan.htm">Busulfan</a></td><td><p><span></span> <span>paracetamol</span> <span>possibly inhibits metabolism of <em>intravenous</em></span> <span>busulfan</span> <span>(manufacturer of <em>intravenous</em><span>busulfan</span> advises caution within 72 hours of <span>paracetamol</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>metabolism of </span><span>paracetamol</span> <span>possibly accelerated by</span> <span>carbamazepine</span> <span>(also isolated reports of hepatotoxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int592-colestyramine.htm">Colestyramine</a></td><td><p><span>absorption of </span><span>paracetamol</span> <span>reduced by</span> <span>colestyramine</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Other drugs should be taken at least 1 hour before or 4–6 hours after colestyramine to reduce possible interference with absorption</p></div></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td><p><span>prolonged regular use of </span><span>paracetamol</span> <span>possibly enhances anticoagulant effect of</span> <span>coumarins</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int933-imatinib.htm">Imatinib</a></td><td><p><span>caution with </span><span>paracetamol</span> <span>advised by manufacturer of</span> <span>imatinib</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int613-metoclopramide.htm">Metoclopramide</a></td><td><p><span>rate of absorption of </span><span>paracetamol</span> <span>increased by</span> <span>metoclopramide</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td><p><span>metabolism of </span><span>paracetamol</span> <span>possibly accelerated by</span> <span>phenobarbital</span> <span>(also isolated reports of hepatotoxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span>metabolism of </span><span>paracetamol</span> <span>possibly accelerated by</span> <span>phenytoin</span> <span>(also isolated reports of hepatotoxicity)</span></p></td><td></td></tr></tbody></table><p><strong>NSAIDs</strong> belongs to <strong>Analgesics</strong> and has the following interaction information:</p><div class="cG"><p><strong>Note:</strong> <em>See also </em>Aspirin. Interactions do not generally apply to topical NSAIDs
</p></div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int2-ace-inhibitors.htm">ACE Inhibitors</a></td><td><p><span>increased risk of renal impairment when </span><span>NSAIDs</span> <span>given with</span> <span>ACE inhibitors</span><span>, also hypotensive effect antagonised</span></p></td><td></td></tr><tr><td><a href="bnf_int15-adrenergic-neurone-blockers.htm">Adrenergic Neurone Blockers</a></td><td><p><span></span> <span>NSAIDs</span> <span>antagonise hypotensive effect of</span> <span>adrenergic neurone blockers</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1099-aliskiren.htm">Aliskiren</a></td><td><p><span></span> <span>NSAIDs</span> <span>possibly antagonise hypotensive effect of</span> <span>aliskiren</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int26-alpha-blockers.htm">Alpha-blockers</a></td><td><p><span></span> <span>NSAIDs</span> <span>antagonise hypotensive effect of</span> <span>alpha-blockers</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int107-angiotensin-ii-receptor-antagonists.htm">Angiotensin-II Receptor Antagonists</a></td><td><p><span>increased risk of renal impairment when </span><span>NSAIDs</span> <span>given with</span> <span>angiotensin-II receptor antagonists</span><span>, also hypotensive effect antagonised</span></p></td><td></td></tr><tr><td><a href="bnf_int232-antidepressants-ssri.htm">Antidepressants, SSRI</a></td><td class="cAI"><p><span>increased risk of bleeding when </span><span>NSAIDs</span> <span>given with</span> <span>SSRIs</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int361-aspirin.htm">Aspirin</a></td><td class="cAI"><p><span>avoid concomitant use of </span><span>NSAIDs</span> <span>with</span> <span>aspirin</span> <span>(increased side-effects)</span></p></td><td></td></tr><tr><td><a href="bnf_int617-baclofen.htm">Baclofen</a></td><td><p><span></span> <span>NSAIDs</span> <span>possibly reduce excretion of</span> <span>baclofen</span> <span>(increased risk of toxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int440-beta-blockers.htm">Beta-blockers</a></td><td><p><span></span> <span>NSAIDs</span> <span>antagonise hypotensive effect of</span> <span>beta-blockers</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Since systemic absorption may follow topical application of beta-blockers to the eye the possibility of interactions, in particular, with drugs such as verapamil should be borne in mind</p></div></td></tr><tr><td><a href="bnf_int466-calcium-channel-blockers.htm">Calcium-channel Blockers</a></td><td><p><span></span> <span>NSAIDs</span> <span>antagonise hypotensive effect of</span> <span>calcium-channel blockers</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int478-cardiac-glycosides.htm">Cardiac Glycosides</a></td><td><p><span></span> <span>NSAIDs</span> <span>possibly increase plasma concentration of</span> <span>cardiac glycosides</span><span>, also possible exacerbation of heart failure and reduction of renal function</span></p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span>increased risk of nephrotoxicity when </span><span>NSAIDs</span> <span>given with</span> <span>ciclosporin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int482-clonidine.htm">Clonidine</a></td><td><p><span></span> <span>NSAIDs</span> <span>antagonise hypotensive effect of</span> <span>clonidine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int865-clopidogrel.htm">Clopidogrel</a></td><td><p><span>increased risk of bleeding when </span><span>NSAIDs</span> <span>given with</span> <span>clopidogrel</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int484-corticosteroids.htm">Corticosteroids</a></td><td><p><span>increased risk of gastro-intestinal bleeding and ulceration when </span><span>NSAIDs</span> <span>given with</span> <span>corticosteroids</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to corticosteroids used for topical action (including inhalation) unless specified</p></div></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>NSAIDs</span> <span>possibly enhance anticoagulant effect of</span> <span>coumarins</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int1120-dabigatran-etexilate.htm">Dabigatran Etexilate</a></td><td class="cAI"><p><span>possible increased risk of bleeding when </span><span>NSAIDs</span> <span>given with</span> <span>dabigatran etexilate</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int522-diazoxide.htm">Diazoxide</a></td><td><p><span></span> <span>NSAIDs</span> <span>antagonise hypotensive effect of</span> <span>diazoxide</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int524-diuretics.htm">Diuretics</a></td><td><p><span>risk of nephrotoxicity of </span><span>NSAIDs</span> <span>increased by</span> <span>diuretics</span><span>, also antagonism of diuretic effect</span></p></td><td></td></tr><tr><td><a href="bnf_int544-diuretics-potassium-sparing-and-aldosterone-antagonists.htm">Diuretics, Potassium-sparing and Aldosterone Antagonists</a></td><td><p><span>possible increased risk of hyperkalaemia when </span><span>NSAIDs</span> <span>given with</span> <span>potassium-sparing diuretics and aldosterone antagonists</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1048-erlotinib.htm">Erlotinib</a></td><td class="cAI"><p><span>increased risk of bleeding when </span><span>NSAIDs</span> <span>given with</span> <span>erlotinib</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int224-heparins.htm">Heparins</a></td><td><p><span>possible increased risk of bleeding when </span><span>NSAIDs</span> <span>given with</span> <span>heparins</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int763-hydralazine.htm">Hydralazine</a></td><td><p><span></span> <span>NSAIDs</span> <span>antagonise hypotensive effect of</span> <span>hydralazine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1015-iloprost.htm">Iloprost</a></td><td><p><span>increased risk of bleeding when </span><span>NSAIDs</span> <span>given with</span> <span>iloprost</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int72-ketorolac.htm">Ketorolac</a></td><td class="cAI"><p><span>avoid concomitant use of </span><span>NSAIDs</span> <span>with</span> <span>ketorolac</span> <span>(increased side-effects and haemorrhage)</span></p></td><td></td></tr><tr><td><a href="bnf_int372-lithium.htm">Lithium</a></td><td class="cAI"><p><span></span> <span>NSAIDs</span> <span>reduce excretion of</span> <span>lithium</span> <span>(increased risk of toxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int511-methotrexate.htm">Methotrexate</a></td><td class="cAI"><p><span></span> <span>NSAIDs</span> <span>probably reduce excretion of</span> <span>methotrexate</span> <span>(increased risk of toxicity)—but for concomitant use in rheumatic disease see <a title="target-block: methotrexate cautions 10.1.3" href="PHP6599-methotrexate.htm#PHP6600">Methotrexate, section 10.1.3</a></span></p></td><td></td></tr><tr><td><a href="bnf_int611-methyldopa.htm">Methyldopa</a></td><td><p><span></span> <span>NSAIDs</span> <span>antagonise hypotensive effect of</span> <span>methyldopa</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1173-mifamurtide.htm">Mifamurtide</a></td><td><p><span>avoidance of high doses of </span><span>NSAIDs</span> <span>advised by manufacturer of</span> <span>mifamurtide</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int764-minoxidil.htm">Minoxidil</a></td><td><p><span></span> <span>NSAIDs</span> <span>antagonise hypotensive effect of</span> <span>minoxidil</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int615-moxonidine.htm">Moxonidine</a></td><td><p><span></span> <span>NSAIDs</span> <span>antagonise hypotensive effect of</span> <span>moxonidine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int60-nsaids.htm">NSAIDs</a></td><td class="cAI"><p><span>avoid concomitant use of </span><span>NSAIDs</span> <span>with</span> <span>NSAIDs</span> <span>(increased side-effects)</span></p></td><td><div class="cG"><p><strong>Note:</strong> <em>See also </em>Aspirin. Interactions do not generally apply to topical NSAIDs
</p></div></td></tr><tr><td><a href="bnf_int631-nitrates.htm">Nitrates</a></td><td><p><span></span> <span>NSAIDs</span> <span>antagonise hypotensive effect of</span> <span>nitrates</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int658-penicillamine.htm">Penicillamine</a></td><td><p><span>possible increased risk of nephrotoxicity when </span><span>NSAIDs</span> <span>given with</span> <span>penicillamine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int826-pentoxifylline.htm">Pentoxifylline</a></td><td><p><span>possible increased risk of bleeding when </span><span>NSAIDs</span> <span>given with</span> <span>pentoxifylline</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int223-phenindione.htm">Phenindione</a></td><td class="cAI"><p><span></span> <span>NSAIDs</span> <span>possibly enhance anticoagulant effect of</span> <span>phenindione</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control  </p></div></td></tr><tr><td><a href="bnf_int1110-potassium-canrenoate.htm">Potassium Canrenoate</a></td><td><p><span></span> <span>NSAIDs</span> <span>possibly antagonise diuretic effect of</span> <span>potassium canrenoate</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1146-prasugrel.htm">Prasugrel</a></td><td><p><span>possible increased risk of bleeding when </span><span>NSAIDs</span> <span>given with</span> <span>prasugrel</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int193-quinolones.htm">Quinolones</a></td><td class="cAI"><p><span>possible increased risk of convulsions when </span><span>NSAIDs</span> <span>given with</span> <span>quinolones</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td><p><span>plasma concentration of </span><span>NSAIDs</span> <span>possibly increased by</span> <span>ritonavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int765-sodium-nitroprusside.htm">Sodium Nitroprusside</a></td><td><p><span></span> <span>NSAIDs</span> <span>antagonise hypotensive effect of</span> <span>sodium nitroprusside</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int268-sulfonylureas.htm">Sulfonylureas</a></td><td class="cAI"><p><span></span> <span>NSAIDs</span> <span>possibly enhance effects of</span> <span>sulfonylureas</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int730-tacrolimus.htm">Tacrolimus</a></td><td><p><span>possible increased risk of nephrotoxicity when </span><span>NSAIDs</span> <span>given with</span> <span>tacrolimus</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="PHP7780-tacrolimus.htm">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</p></div></td></tr><tr><td><a href="bnf_int240-venlafaxine.htm">Venlafaxine</a></td><td class="cAI"><p><span>increased risk of bleeding when </span><span>NSAIDs</span> <span>given with</span> <span>venlafaxine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int403-zidovudine.htm">Zidovudine</a></td><td><p><span>increased risk of haematological toxicity when </span><span>NSAIDs</span> <span>given with</span> <span>zidovudine</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Increased risk of toxicity with nephrotoxic and myelosuppressive drugs—for further details consult product literature</p></div></td></tr></tbody></table><p><strong>Dexibuprofen</strong> belongs to <strong>Analgesics</strong> but has no specific interaction information.</p><p><strong>Parecoxib</strong> belongs to <strong>Analgesics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int301-fluconazole.htm">Fluconazole</a></td><td><p><span>plasma concentration of </span><span>parecoxib</span> <span>increased by</span> <span>fluconazole</span> <span>(reduce dose of <span>parecoxib</span>)</span></p></td><td><div class="cG"><p><strong>Note:</strong> In general, fluconazole interactions relate to multiple-dose treatment</p></div></td></tr></tbody></table><p><strong>Etoricoxib</strong> belongs to <strong>Analgesics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int638-ethinylestradiol.htm">Ethinylestradiol</a></td><td><p><span></span> <span>etoricoxib</span> <span>increases plasma concentration of</span> <span>ethinylestradiol</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>plasma concentration of </span><span>etoricoxib</span> <span>reduced by</span> <span>rifampicin</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Aceclofenac</strong> belongs to <strong>Analgesics</strong> but has no specific interaction information.</p><p><strong>Acemetacin</strong> belongs to <strong>Analgesics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int387-haloperidol.htm">Haloperidol</a></td><td><p><span>possible severe drowsiness when </span><span>acemetacin</span> <span>given with</span> <span>haloperidol</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int663-probenecid.htm">Probenecid</a></td><td class="cAI"><p><span>excretion of </span><span>acemetacin</span> <span>reduced by</span> <span>probenecid</span> <span>(increased plasma concentration)</span></p></td><td></td></tr></tbody></table><p><strong>Celecoxib</strong> belongs to <strong>Analgesics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int301-fluconazole.htm">Fluconazole</a></td><td><p><span>plasma concentration of </span><span>celecoxib</span> <span>increased by</span> <span>fluconazole</span> <span>(halve dose of <span>celecoxib</span>)</span></p></td><td><div class="cG"><p><strong>Note:</strong> In general, fluconazole interactions relate to multiple-dose treatment</p></div></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>plasma concentration of </span><span>celecoxib</span> <span>reduced by</span> <span>rifampicin</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Dexketoprofen</strong> belongs to <strong>Analgesics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int663-probenecid.htm">Probenecid</a></td><td class="cAI"><p><span>excretion of </span><span>dexketoprofen</span> <span>reduced by</span> <span>probenecid</span> <span>(increased plasma concentration)</span></p></td><td></td></tr></tbody></table><p><strong>Diclofenac</strong> belongs to <strong>Analgesics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int219-anticoagulants.htm">Anticoagulants</a></td><td class="cAI"><p><span>increased risk of haemorrhage when <em>intravenous</em></span> <span>diclofenac</span> <span>given with</span> <span>anticoagulants</span> <span>(avoid concomitant use, including low-dose heparins)</span></p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span>plasma concentration of </span><span>diclofenac</span> <span>increased by</span> <span>ciclosporin</span> <span>(halve dose of <span>diclofenac</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int511-methotrexate.htm">Methotrexate</a></td><td class="cAI"><p><span></span> <span>diclofenac</span> <span>reduces excretion of</span> <span>methotrexate</span> <span>(increased risk of toxicity)—but for concomitant use in rheumatic disease see <a title="target-block: methotrexate cautions 10.1.3" href="PHP6599-methotrexate.htm#PHP6600">Methotrexate, section 10.1.3</a></span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>plasma concentration of </span><span>diclofenac</span> <span>reduced by</span> <span>rifampicin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int948-voriconazole.htm">Voriconazole</a></td><td><p><span>plasma concentration of </span><span>diclofenac</span> <span>increased by</span> <span>voriconazole</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Etodolac</strong> belongs to <strong>Analgesics</strong> but has no specific interaction information.</p><p><strong>Fenoprofen</strong> belongs to <strong>Analgesics</strong> but has no specific interaction information.</p><p><strong>Flurbiprofen</strong> belongs to <strong>Analgesics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int301-fluconazole.htm">Fluconazole</a></td><td><p><span>plasma concentration of </span><span>flurbiprofen</span> <span>increased by</span> <span>fluconazole</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> In general, fluconazole interactions relate to multiple-dose treatment</p></div></td></tr></tbody></table><p><strong>Ibuprofen</strong> belongs to <strong>Analgesics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int361-aspirin.htm">Aspirin</a></td><td><p><span></span> <span>ibuprofen</span> <span>possibly reduces antiplatelet effect of</span> <span>aspirin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int617-baclofen.htm">Baclofen</a></td><td><p><span></span> <span>ibuprofen</span> <span>reduces excretion of</span> <span>baclofen</span> <span>(increased risk of toxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int301-fluconazole.htm">Fluconazole</a></td><td><p><span>plasma concentration of </span><span>ibuprofen</span> <span>increased by</span> <span>fluconazole</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> In general, fluconazole interactions relate to multiple-dose treatment</p></div></td></tr><tr><td><a href="bnf_int511-methotrexate.htm">Methotrexate</a></td><td class="cAI"><p><span></span> <span>ibuprofen</span> <span>reduces excretion of</span> <span>methotrexate</span> <span>(increased risk of toxicity)—but for concomitant use in rheumatic disease see <a title="target-block: methotrexate cautions 10.1.3" href="PHP6599-methotrexate.htm#PHP6600">Methotrexate, section 10.1.3</a></span></p></td><td></td></tr><tr><td><a href="bnf_int730-tacrolimus.htm">Tacrolimus</a></td><td class="cAI"><p><span>increased risk of nephrotoxicity when </span><span>ibuprofen</span> <span>given with</span> <span>tacrolimus</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="PHP7780-tacrolimus.htm">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</p></div></td></tr><tr><td><a href="bnf_int948-voriconazole.htm">Voriconazole</a></td><td><p><span>plasma concentration of </span><span>ibuprofen</span> <span>increased by</span> <span>voriconazole</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Indometacin</strong> belongs to <strong>Analgesics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int129-amikacin.htm">Amikacin</a></td><td><p><span></span> <span>indometacin</span> <span>possibly increases plasma concentration of</span> <span>amikacin</span> <span>in neonates</span></p></td><td></td></tr><tr><td><a href="bnf_int795-desmopressin.htm">Desmopressin</a></td><td><p><span></span> <span>indometacin</span> <span>enhances effects of</span> <span>desmopressin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int524-diuretics.htm">Diuretics</a></td><td><p><span></span> <span>indometacin</span> <span>antagonises effects of</span> <span>diuretics</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int544-diuretics-potassium-sparing-and-aldosterone-antagonists.htm">Diuretics, Potassium-sparing and Aldosterone Antagonists</a></td><td><p><span>increased risk of hyperkalaemia when </span><span>indometacin</span> <span>given with</span> <span>potassium-sparing diuretics and aldosterone antagonists</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int131-gentamicin.htm">Gentamicin</a></td><td><p><span></span> <span>indometacin</span> <span>possibly increases plasma concentration of</span> <span>gentamicin</span> <span>in neonates</span></p></td><td></td></tr><tr><td><a href="bnf_int387-haloperidol.htm">Haloperidol</a></td><td><p><span>possible severe drowsiness when </span><span>indometacin</span> <span>given with</span> <span>haloperidol</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int511-methotrexate.htm">Methotrexate</a></td><td class="cAI"><p><span></span> <span>indometacin</span> <span>reduces excretion of</span> <span>methotrexate</span> <span>(increased risk of toxicity)—but for concomitant use in rheumatic disease see <a title="target-block: methotrexate cautions 10.1.3" href="PHP6599-methotrexate.htm#PHP6600">Methotrexate, section 10.1.3</a></span></p></td><td></td></tr><tr><td><a href="bnf_int663-probenecid.htm">Probenecid</a></td><td class="cAI"><p><span>excretion of </span><span>indometacin</span> <span>reduced by</span> <span>probenecid</span> <span>(increased plasma concentration)</span></p></td><td></td></tr><tr><td><a href="bnf_int546-triamterene.htm">Triamterene</a></td><td class="cAI"><p><span>occasional reports of reduced renal function when </span><span>indometacin</span> <span>given with</span> <span>triamterene</span><span>—avoid concomitant use</span></p></td><td></td></tr></tbody></table><p><strong>Ketoprofen</strong> belongs to <strong>Analgesics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int511-methotrexate.htm">Methotrexate</a></td><td class="cAI"><p><span></span> <span>ketoprofen</span> <span>reduces excretion of</span> <span>methotrexate</span> <span>(increased risk of toxicity)—but for concomitant use in rheumatic disease see <a title="target-block: methotrexate cautions 10.1.3" href="PHP6599-methotrexate.htm#PHP6600">Methotrexate, section 10.1.3</a></span></p></td><td></td></tr><tr><td><a href="bnf_int663-probenecid.htm">Probenecid</a></td><td class="cAI"><p><span>excretion of </span><span>ketoprofen</span> <span>reduced by</span> <span>probenecid</span> <span>(increased plasma concentration)</span></p></td><td></td></tr></tbody></table><p><strong>Ketorolac</strong> belongs to <strong>Analgesics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int219-anticoagulants.htm">Anticoagulants</a></td><td class="cAI"><p><span>increased risk of haemorrhage when </span><span>ketorolac</span> <span>given with</span> <span>anticoagulants</span> <span>(avoid concomitant use, including low-dose heparins)</span></p></td><td></td></tr><tr><td><a href="bnf_int524-diuretics.htm">Diuretics</a></td><td><p><span></span> <span>ketorolac</span> <span>antagonises effects of</span> <span>diuretics</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int372-lithium.htm">Lithium</a></td><td class="cAI"><p><span></span> <span>ketorolac</span> <span>reduces excretion of</span> <span>lithium</span> <span>(increased risk of toxicity)—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int60-nsaids.htm">NSAIDs</a></td><td class="cAI"><p><span>avoid concomitant use of </span><span>ketorolac</span> <span>with</span> <span>NSAIDs</span> <span>(increased side-effects and haemorrhage)</span></p></td><td><div class="cG"><p><strong>Note:</strong> <em>See also </em>Aspirin. Interactions do not generally apply to topical NSAIDs
</p></div></td></tr><tr><td><a href="bnf_int826-pentoxifylline.htm">Pentoxifylline</a></td><td class="cAI"><p><span>increased risk of bleeding  when </span><span>ketorolac</span> <span>given with</span> <span>pentoxifylline</span> <span>(avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int663-probenecid.htm">Probenecid</a></td><td class="cAI"><p><span>excretion of </span><span>ketorolac</span> <span>reduced by</span> <span>probenecid</span> <span>(increased plasma concentration)—avoid concomitant use</span></p></td><td></td></tr></tbody></table><p><strong>Mefenamic Acid</strong> belongs to <strong>Analgesics</strong> but has no specific interaction information.</p><p><strong>Meloxicam</strong> belongs to <strong>Analgesics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int592-colestyramine.htm">Colestyramine</a></td><td><p><span>excretion of </span><span>meloxicam</span> <span>increased by</span> <span>colestyramine</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Other drugs should be taken at least 1 hour before or 4–6 hours after colestyramine to reduce possible interference with absorption</p></div></td></tr><tr><td><a href="bnf_int511-methotrexate.htm">Methotrexate</a></td><td class="cAI"><p><span></span> <span>meloxicam</span> <span>reduces excretion of</span> <span>methotrexate</span> <span>(increased risk of toxicity)—but for concomitant use in rheumatic disease see <a title="target-block: methotrexate cautions 10.1.3" href="PHP6599-methotrexate.htm#PHP6600">Methotrexate, section 10.1.3</a></span></p></td><td></td></tr></tbody></table><p><strong>Nabumetone</strong> belongs to <strong>Analgesics</strong> but has no specific interaction information.</p><p><strong>Naproxen</strong> belongs to <strong>Analgesics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int511-methotrexate.htm">Methotrexate</a></td><td class="cAI"><p><span></span> <span>naproxen</span> <span>reduces excretion of</span> <span>methotrexate</span> <span>(increased risk of toxicity)—but for concomitant use in rheumatic disease see <a title="target-block: methotrexate cautions 10.1.3" href="PHP6599-methotrexate.htm#PHP6600">Methotrexate, section 10.1.3</a></span></p></td><td></td></tr><tr><td><a href="bnf_int663-probenecid.htm">Probenecid</a></td><td class="cAI"><p><span>excretion of </span><span>naproxen</span> <span>reduced by</span> <span>probenecid</span> <span>(increased plasma concentration)</span></p></td><td></td></tr></tbody></table><p><strong>Piroxicam</strong> belongs to <strong>Analgesics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>plasma concentration of </span><span>piroxicam</span> <span>increased by</span> <span>ritonavir</span> <span>(risk of toxicity)—avoid concomitant use</span></p></td><td></td></tr></tbody></table><p><strong>Sulindac</strong> belongs to <strong>Analgesics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1130-dimethyl-sulfoxide.htm">Dimethyl sulfoxide</a></td><td class="cAI"><p><span>avoid concomitant use of </span><span>sulindac</span> <span>with</span> <span>dimethyl sulfoxide</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Tenoxicam</strong> belongs to <strong>Analgesics</strong> but has no specific interaction information.</p><p><strong>Tiaprofenic Acid</strong> belongs to <strong>Analgesics</strong> but has no specific interaction information.</p><p><strong>Tolfenamic Acid</strong> belongs to <strong>Analgesics</strong> but has no specific interaction information.</p><p><strong>Opioid Analgesics</strong> belongs to <strong>Analgesics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int20-alcohol.htm">Alcohol</a></td><td><p><span>enhanced hypotensive and sedative effects when </span><span>opioid analgesics</span> <span>given with</span> <span>alcohol</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int40-anaesthetics-general-intravenous.htm">Anaesthetics, General (intravenous)</a></td><td><p><span></span> <span>opioid analgesics</span> <span>possibly enhance effects of</span> <span>intravenous general anaesthetics</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int46-anaesthetics-general-volatile-liquids.htm">Anaesthetics, General (volatile liquids)</a></td><td><p><span></span> <span>opioid analgesics</span> <span>possibly enhance effects of</span> <span>volatile liquid general anaesthetics</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int241-antidepressants-tricyclic.htm">Antidepressants, Tricyclic</a></td><td><p><span>sedative effects possibly increased when </span><span>opioid analgesics</span> <span>given with</span> <span>tricyclics</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int311-antihistamines-sedating.htm">Antihistamines, Sedating</a></td><td class="cAI"><p><span>sedative effects possibly increased when </span><span>opioid analgesics</span> <span>given with</span> <span>sedating antihistamines</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int363-antipsychotics.htm">Antipsychotics</a></td><td><p><span>enhanced hypotensive and sedative effects when </span><span>opioid analgesics</span> <span>given with</span> <span>antipsychotics</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Increased risk of toxicity with myelosuppressive drugs</p></div></td></tr><tr><td><a href="bnf_int404-anxiolytics-and-hypnotics.htm">Anxiolytics and Hypnotics</a></td><td><p><span>increased sedative effect when </span><span>opioid analgesics</span> <span>given with</span> <span>anxiolytics and hypnotics</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td><p><span>metabolism of </span><span>opioid analgesics</span> <span>inhibited by</span> <span>cimetidine</span> <span>(increased plasma concentration)</span></p></td><td></td></tr><tr><td><a href="bnf_int553-domperidone.htm">Domperidone</a></td><td><p><span></span> <span>opioid analgesics</span> <span>antagonise effects of</span> <span>domperidone</span> <span>on gastro-intestinal activity</span></p></td><td></td></tr><tr><td><a href="bnf_int257-maois.htm">MAOIs</a></td><td class="cAI"><p><span>possible CNS excitation or depression (hypertension or hypotension) when </span><span>opioid analgesics</span> <span>given with</span> <span>MAOIs</span><span>—some manufacturers advise avoid concomitant use and for 2 weeks after stopping <span>MAOIs</span></span></p></td><td><div class="cG"><p><strong>Note:</strong> For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</p></div></td></tr><tr><td><a href="bnf_int613-metoclopramide.htm">Metoclopramide</a></td><td><p><span></span> <span>opioid analgesics</span> <span>antagonise effects of</span> <span>metoclopramide</span> <span>on gastro-intestinal activity</span></p></td><td></td></tr><tr><td><a href="bnf_int262-moclobemide.htm">Moclobemide</a></td><td class="cAI"><p><span>possible CNS excitation or depression (hypertension or hypotension) when </span><span>opioid analgesics</span> <span>given with</span> <span>moclobemide</span><span>—manufacturer of <span>moclobemide</span> advises consider reducing dose of <span>opioid analgesics</span></span></p></td><td></td></tr><tr><td><a href="bnf_int687-selegiline.htm">Selegiline</a></td><td><p><span>avoidance of </span><span>opioid analgesics</span> <span>advised by manufacturer of</span> <span>selegiline</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Selegiline is a MAO-B inhibitor</p></div></td></tr><tr><td><a href="bnf_int1067-sodium-oxybate.htm">Sodium Oxybate</a></td><td class="cAI"><p><span></span> <span>opioid analgesics</span> <span>enhance effects of</span> <span>sodium oxybate</span> <span>(avoid concomitant use)</span></p></td><td></td></tr></tbody></table><p><strong>Tapentadol</strong> belongs to <strong>Analgesics</strong> but has no specific interaction information.</p><p><strong>Alfentanil</strong> belongs to <strong>Analgesics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1240-crizotinib.htm">Crizotinib</a></td><td class="cAI"><p><span>caution with </span><span>alfentanil</span> <span>advised by manufacturer of</span> <span>crizotinib</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int468-diltiazem.htm">Diltiazem</a></td><td><p><span>metabolism of </span><span>alfentanil</span> <span>inhibited by</span> <span>diltiazem</span> <span>(risk of prolonged or delayed respiratory depression)</span></p></td><td></td></tr><tr><td><a href="bnf_int169-erythromycin.htm">Erythromycin</a></td><td><p><span>plasma concentration of </span><span>alfentanil</span> <span>increased by</span> <span>erythromycin</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to small amounts of erythromycin used topically</p></div></td></tr><tr><td><a href="bnf_int301-fluconazole.htm">Fluconazole</a></td><td><p><span>metabolism of </span><span>alfentanil</span> <span>inhibited by</span> <span>fluconazole</span> <span>(risk of prolonged or delayed respiratory depression)</span></p></td><td><div class="cG"><p><strong>Note:</strong> In general, fluconazole interactions relate to multiple-dose treatment</p></div></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td><p><span>metabolism of </span><span>alfentanil</span> <span>possibly inhibited by</span> <span>itraconazole</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>metabolism of </span><span>alfentanil</span> <span>accelerated by</span> <span>rifampicin</span> <span>(reduced effect)</span></p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>plasma concentration of </span><span>alfentanil</span> <span>increased by</span> <span>ritonavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>alfentanil</span> <span>given with</span> <span>saquinavir</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int948-voriconazole.htm">Voriconazole</a></td><td class="cAI"><p><span>plasma concentration of </span><span>alfentanil</span> <span>increased by</span> <span>voriconazole</span> <span>(consider reducing dose of <span>alfentanil</span>)</span></p></td><td></td></tr></tbody></table><p><strong>Buprenorphine</strong> belongs to <strong>Analgesics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td class="cAI"><p><span>metabolism of </span><span>buprenorphine</span> <span>inhibited by</span> <span>ketoconazole</span> <span>(reduce dose of <span>buprenorphine</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td><p><span>plasma concentration of </span><span>buprenorphine</span> <span>possibly increased by</span> <span>ritonavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1055-tipranavir.htm">Tipranavir</a></td><td><p><span></span> <span>buprenorphine</span> <span>possibly reduces plasma concentration of</span> <span>tipranavir</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Codeine</strong> belongs to <strong>Analgesics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int342-antimuscarinics.htm">Antimuscarinics</a></td><td><p><span>possible increased risk of antimuscarinic side-effects when </span><span>codeine</span> <span>given with</span> <span>antimuscarinics</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Many drugs have antimuscarinic effects; concomitant use of two or more such drugs can increase side-effects such as dry mouth, urine retention, and constipation; concomitant use can also lead to confusion in the elderly. Interactions do not generally apply to antimuscarinics used by inhalation</p></div></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>metabolism of </span><span>codeine</span> <span>accelerated by</span> <span>rifampicin</span> <span>(reduced effect)</span></p></td><td></td></tr></tbody></table><p><strong>Dextromethorphan</strong> belongs to <strong>Analgesics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int942-memantine.htm">Memantine</a></td><td class="cAI"><p><span>increased risk of CNS toxicity when </span><span>dextromethorphan</span> <span>given with</span> <span>memantine</span> <span>(manufacturer of <span>memantine</span> advises avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int262-moclobemide.htm">Moclobemide</a></td><td class="cAI"><p><span>possible CNS excitation or depression (hypertension or hypotension) when </span><span>dextromethorphan</span> <span>given with</span> <span>moclobemide</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1051-rasagiline.htm">Rasagiline</a></td><td class="cAI"><p><span>avoid concomitant use of </span><span>dextromethorphan</span> <span>with</span> <span>rasagiline</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Rasagiline is a MAO-B inhibitor</p></div></td></tr></tbody></table><p><strong>Dextropropoxyphene</strong> belongs to <strong>Analgesics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td class="cAI"><p><span></span> <span>dextropropoxyphene</span> <span>enhances effects of</span> <span>carbamazepine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>plasma concentration of </span><span>dextropropoxyphene</span> <span>increased by</span> <span>ritonavir</span> <span>(risk of toxicity)—avoid concomitant use</span></p></td><td></td></tr></tbody></table><p><strong>Diamorphine</strong> belongs to <strong>Analgesics</strong> but has no specific interaction information.</p><p><strong>Dihydrocodeine</strong> belongs to <strong>Analgesics</strong> but has no specific interaction information.</p><p><strong>Diphenoxylate</strong> belongs to <strong>Analgesics</strong> but has no specific interaction information.</p><p><strong>Dipipanone</strong> belongs to <strong>Analgesics</strong> but has no specific interaction information.</p><p><strong>Fentanyl</strong> belongs to <strong>Analgesics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int300-antifungals-triazole.htm">Antifungals, Triazole</a></td><td class="cAI"><p><span>plasma concentration of </span><span>fentanyl</span> <span>possibly increased by</span> <span>triazoles</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int617-baclofen.htm">Baclofen</a></td><td><p><span>increased sedative effect when </span><span>fentanyl</span> <span>given with</span> <span>baclofen</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1240-crizotinib.htm">Crizotinib</a></td><td class="cAI"><p><span>caution with </span><span>fentanyl</span> <span>advised by manufacturer of</span> <span>crizotinib</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int43-etomidate.htm">Etomidate</a></td><td><p><span></span> <span>fentanyl</span> <span>inhibits metabolism of</span> <span>etomidate</span> <span>(consider reducing dose of <span>etomidate</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int421-midazolam.htm">Midazolam</a></td><td><p><span></span> <span>fentanyl</span> <span>possibly inhibits metabolism of</span> <span>midazolam</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>metabolism of </span><span>fentanyl</span> <span>accelerated by</span> <span>rifampicin</span> <span>(reduced effect)</span></p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>plasma concentration of </span><span>fentanyl</span> <span>increased by</span> <span>ritonavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>fentanyl</span> <span>given with</span> <span>saquinavir</span><span>—avoid concomitant use</span></p></td><td></td></tr></tbody></table><p><strong>Hydromorphone</strong> belongs to <strong>Analgesics</strong> but has no specific interaction information.</p><p><strong>Meptazinol</strong> belongs to <strong>Analgesics</strong> but has no specific interaction information.</p><p><strong>Methadone</strong> belongs to <strong>Analgesics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int907-abacavir.htm">Abacavir</a></td><td><p><span>plasma concentration of </span><span>methadone</span> <span>possibly reduced by</span> <span>abacavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int809-amisulpride.htm">Amisulpride</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>methadone</span> <span>given with</span> <span>amisulpride</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int363-antipsychotics.htm">Antipsychotics</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>methadone</span> <span>given with</span> <span>antipsychotics</span> <span>that prolong the QT interval</span></p></td><td><div class="cG"><p><strong>Note:</strong> Increased risk of toxicity with myelosuppressive drugs</p></div></td></tr><tr><td><a href="bnf_int1009-atomoxetine.htm">Atomoxetine</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>methadone</span> <span>given with</span> <span>atomoxetine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1214-boceprevir.htm">Boceprevir</a></td><td><p><span>plasma concentration of </span><span>methadone</span> <span>possibly affected by</span> <span>boceprevir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>plasma concentration of </span><span>methadone</span> <span>reduced by</span> <span>carbamazepine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int397-didanosine.htm">Didanosine</a></td><td><p><span></span> <span>methadone</span> <span>possibly reduces plasma concentration of</span> <span>didanosine</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Antacids in tablet formulation may affect absorption of other drugs</p></div></td></tr><tr><td><a href="bnf_int874-efavirenz.htm">Efavirenz</a></td><td><p><span>plasma concentration of </span><span>methadone</span> <span>reduced by</span> <span>efavirenz</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int301-fluconazole.htm">Fluconazole</a></td><td><p><span>plasma concentration of </span><span>methadone</span> <span>increased by</span> <span>fluconazole</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> In general, fluconazole interactions relate to multiple-dose treatment</p></div></td></tr><tr><td><a href="bnf_int234-fluoxetine.htm">Fluoxetine</a></td><td><p><span>plasma concentration of </span><span>methadone</span> <span>possibly increased by</span> <span>fluoxetine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int235-fluvoxamine.htm">Fluvoxamine</a></td><td><p><span>plasma concentration of </span><span>methadone</span> <span>possibly increased by</span> <span>fluvoxamine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1019-fosamprenavir.htm">Fosamprenavir</a></td><td><p><span>plasma concentration of </span><span>methadone</span> <span>reduced by</span> <span>fosamprenavir</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Fosamprenavir is a prodrug of amprenavir</p></div></td></tr><tr><td><a href="bnf_int843-nevirapine.htm">Nevirapine</a></td><td><p><span>plasma concentration of </span><span>methadone</span> <span>possibly reduced by</span> <span>nevirapine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int236-paroxetine.htm">Paroxetine</a></td><td><p><span>plasma concentration of </span><span>methadone</span> <span>possibly increased by</span> <span>paroxetine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td><p><span>plasma concentration of </span><span>methadone</span> <span>reduced by</span> <span>phenobarbital</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span>metabolism of </span><span>methadone</span> <span>accelerated by</span> <span>phenytoin</span> <span>(reduced effect and risk of withdrawal effects)</span></p></td><td></td></tr><tr><td><a href="bnf_int1237-piperaquine-with-artenimol.htm">Piperaquine with Artenimol</a></td><td class="cAI"><p><span>avoidance of </span><span>methadone</span> <span>advised by manufacturer of</span> <span>piperaquine with artenimol</span> <span>(possible risk of ventricular arrhythmias)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Piperaquine has a long half-life; there is a potential for drug interactions to occur for up to 3 months after treatment has been stopped</p></div></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>metabolism of </span><span>methadone</span> <span>accelerated by</span> <span>rifampicin</span> <span>(reduced effect)</span></p></td><td></td></tr><tr><td><a href="bnf_int1225-rilpivirine.htm">Rilpivirine</a></td><td><p><span>plasma concentration of </span><span>methadone</span> <span>possibly reduced by</span> <span>rilpivirine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td><p><span>plasma concentration of </span><span>methadone</span> <span>reduced by</span> <span>ritonavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>methadone</span> <span>given with</span> <span>saquinavir</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int237-sertraline.htm">Sertraline</a></td><td><p><span>plasma concentration of </span><span>methadone</span> <span>possibly increased by</span> <span>sertraline</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td><p><span>plasma concentration of </span><span>methadone</span> <span>possibly reduced by</span> <span>St John's wort</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1216-telaprevir.htm">Telaprevir</a></td><td class="cAI"><p><span>caution with </span><span>methadone</span> <span>advised by manufacturer of</span> <span>telaprevir</span> <span>(risk of ventricular arrhythmias)</span></p></td><td></td></tr><tr><td><a href="bnf_int946-telithromycin.htm">Telithromycin</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span><span>methadone</span> <span>given with</span> <span>telithromycin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1227-vandetanib.htm">Vandetanib</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span><span>methadone</span> <span>given with</span> <span>vandetanib</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int948-voriconazole.htm">Voriconazole</a></td><td class="cAI"><p><span>plasma concentration of </span><span>methadone</span> <span>increased by</span> <span>voriconazole</span> <span>(consider reducing dose of <span>methadone</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int403-zidovudine.htm">Zidovudine</a></td><td><p><span></span> <span>methadone</span> <span>possibly increases plasma concentration of</span> <span>zidovudine</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Increased risk of toxicity with nephrotoxic and myelosuppressive drugs—for further details consult product literature</p></div></td></tr></tbody></table><p><strong>Morphine</strong> belongs to <strong>Analgesics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int617-baclofen.htm">Baclofen</a></td><td><p><span>increased sedative effect when </span><span>morphine</span> <span>given with</span> <span>baclofen</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int447-esmolol.htm">Esmolol</a></td><td><p><span></span> <span>morphine</span> <span>possibly increases plasma concentration of</span> <span>esmolol</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int282-gabapentin.htm">Gabapentin</a></td><td><p><span></span> <span>morphine</span> <span>increases bioavailability of</span> <span>gabapentin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>metabolism of </span><span>morphine</span> <span>accelerated by</span> <span>rifampicin</span> <span>(reduced effect)</span></p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td><p><span>plasma concentration of </span><span>morphine</span> <span>possibly reduced by</span> <span>ritonavir</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Oxycodone</strong> belongs to <strong>Analgesics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>metabolism of </span><span>oxycodone</span> <span>possibly accelerated by</span> <span>rifampicin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int946-telithromycin.htm">Telithromycin</a></td><td><p><span>metabolism of </span><span>oxycodone</span> <span>inhibited by</span> <span>telithromycin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int948-voriconazole.htm">Voriconazole</a></td><td class="cAI"><p><span>plasma concentration of </span><span>oxycodone</span> <span>increased by</span> <span>voriconazole</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Papaveretum</strong> belongs to <strong>Analgesics</strong> but has no specific interaction information.</p><p><strong>Pentazocine</strong> belongs to <strong>Analgesics</strong> but has no specific interaction information.</p><p><strong>Pethidine</strong> belongs to <strong>Analgesics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1024-duloxetine.htm">Duloxetine</a></td><td><p><span>possible increased serotonergic effects when </span><span>pethidine</span> <span>given with</span> <span>duloxetine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int257-maois.htm">MAOIs</a></td><td class="cAI"><p><span>CNS excitation or depression (hypertension or hypotension) when </span><span>pethidine</span> <span>given with</span> <span>MAOIs</span><span>—avoid concomitant use and for 2 weeks after stopping <span>MAOIs</span></span></p></td><td><div class="cG"><p><strong>Note:</strong> For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</p></div></td></tr><tr><td><a href="bnf_int262-moclobemide.htm">Moclobemide</a></td><td class="cAI"><p><span>possible CNS excitation or depression (hypertension or hypotension) when </span><span>pethidine</span> <span>given with</span> <span>moclobemide</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1051-rasagiline.htm">Rasagiline</a></td><td class="cAI"><p><span>risk of CNS toxicity when </span><span>pethidine</span> <span>given with</span> <span>rasagiline</span> <span>(avoid <span>pethidine</span> for 2 weeks after <span>rasagiline</span>)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Rasagiline is a MAO-B inhibitor</p></div></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>plasma concentration of </span><span>pethidine</span> <span>reduced by</span> <span>ritonavir</span><span>, but plasma concentration of toxic <span>pethidine</span> metabolite increased (avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int687-selegiline.htm">Selegiline</a></td><td class="cAI"><p><span>hyperpyrexia and CNS toxicity reported when </span><span>pethidine</span> <span>given with</span> <span>selegiline</span> <span>(avoid concomitant use)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Selegiline is a MAO-B inhibitor</p></div></td></tr></tbody></table><p><strong>Remifentanil</strong> belongs to <strong>Analgesics</strong> but has no specific interaction information.</p><p><strong>Tramadol</strong> belongs to <strong>Analgesics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int232-antidepressants-ssri.htm">Antidepressants, SSRI</a></td><td class="cAI"><p><span>increased risk of CNS toxicity when </span><span>tramadol</span> <span>given with</span> <span>SSRIs</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int241-antidepressants-tricyclic.htm">Antidepressants, Tricyclic</a></td><td class="cAI"><p><span>increased risk of CNS toxicity when </span><span>tramadol</span> <span>given with</span> <span>tricyclics</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int363-antipsychotics.htm">Antipsychotics</a></td><td><p><span>increased risk of convulsions when </span><span>tramadol</span> <span>given with</span> <span>antipsychotics</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Increased risk of toxicity with myelosuppressive drugs</p></div></td></tr><tr><td><a href="bnf_int1009-atomoxetine.htm">Atomoxetine</a></td><td><p><span>possible increased risk of convulsions when </span><span>tramadol</span> <span>given with</span> <span>atomoxetine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>effects of </span><span>tramadol</span> <span>reduced by</span> <span>carbamazepine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>tramadol</span> <span>enhances anticoagulant effect of</span> <span>coumarins</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int1024-duloxetine.htm">Duloxetine</a></td><td><p><span>possible increased serotonergic effects when </span><span>tramadol</span> <span>given with</span> <span>duloxetine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int257-maois.htm">MAOIs</a></td><td class="cAI"><p><span>possible increased serotonergic effects and increased risk of convulsions when </span><span>tramadol</span> <span>given with</span> <span>MAOIs</span><span>—some manufacturers advise avoid concomitant use and for 2 weeks after stopping <span>MAOIs</span></span></p></td><td><div class="cG"><p><strong>Note:</strong> For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</p></div></td></tr><tr><td><a href="bnf_int823-mirtazapine.htm">Mirtazapine</a></td><td><p><span>possible increased serotonergic effects when </span><span>tramadol</span> <span>given with</span> <span>mirtazapine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1045-ondansetron.htm">Ondansetron</a></td><td><p><span>effects of </span><span>tramadol</span> <span>possibly antagonised by</span> <span>ondansetron</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int240-venlafaxine.htm">Venlafaxine</a></td><td><p><span>possible increased serotonergic effects when </span><span>tramadol</span> <span>given with</span> <span>venlafaxine</span> <span></span></p></td><td></td></tr></tbody></table></div><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="bnf_int58-nefopam.htm" title="Nefopam">Nefopam</a></li><li><a href="bnf_int361-aspirin.htm" title="Aspirin">Aspirin</a></li><li><a href="bnf_int59-paracetamol.htm" title="Paracetamol">Paracetamol</a></li><li id="_bnf_int60-nsaids"><a href="bnf_int60-nsaids.htm" title="NSAIDs">NSAIDs</a></li><li id="_bnf_int85-opioid-analgesics"><a href="bnf_int85-opioid-analgesics.htm" title="Opioid Analgesics">Opioid Analgesics</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="bnf_int989-anakinra.htm">Previous: Anakinra</a> | <a class="top" href="bnf_int56-analgesics.htm#">Top</a> | <a accesskey="]" href="bnf_int58-nefopam.htm">Next: Nefopam</a> ►</div></div></div></div><div id="pF"><div id="p2"><div id="pL"><div class="p4"><h2>Keep in touch</h2><ul><li><a href="http://www.pharmpress.com/?utm_source=medicinescomplete&amp;utm_medium=footer&amp;utm_campaign=medicinescomplete-referral">Pharmaceutical Press</a></li><li><a href="http://www.rpharms.com/">Royal Pharmaceutical Society</a></li><li><a href="http://www.pharmpress.com/mc-alerts.asp?utm_source=medicinescomplete&amp;utm_medium=footer&amp;utm_campaign=medicinescomplete-referral">Sign up for our eNewsletter</a></li><li><a href="http://twitter.com/#!/PharmPress/" class="p5"><img src="../../images/twitter.png" alt="Twitter logo" />Follow us on Twitter
              </a></li><li><a href="http://www.facebook.com/pages/Pharmaceutical-Press/296104187066918" class="p5"><img src="../../images/facebook.png" alt="Facebook logo" />Find us on Facebook
              </a></li></ul></div><div class="p4"><h2>Help and Support</h2><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a></li><li><a href="http://www.medicinescomplete.com/about/contact.htm">Contact Us</a></li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a></li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a></li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div><div class="p4"><h2>Provided for</h2><div id="cL"><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2013.  All rights reserved.</a></p><p><a href="http://www.medicinescomplete.com/mc/copyright.htm">MedicinesComplete © The Pharmaceutical Press 2013</a></p></div></div></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>